# Tempus AI wins FDA clearance for two AI-ECG tools

Digest AI · Enterprise & Industry · published 2026-10-05T07:03:00Z

Canonical: https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools

## Summary

**Tempus AI** announced FDA clearance for two AI-powered ECG tools in October 2026, targeting undiagnosed heart conditions. The **Tempus ECG-MR** detects moderate or severe mitral regurgitation from standard 12-lead ECGs, while **Tempus ECG-PH** flags pulmonary hypertension with binary results. Both tools expand Tempus’s cardiovascular AI portfolio amid a market projected to grow from **$2.01 billion in 2025 to $2.40 billion in 2026**, per Business Research, at a **19.3% CAGR**.

The clearances follow **510(k) approvals**, a regulatory pathway for lower-risk medical devices. Tempus’s stock has fallen **17.7%** over the past year, outpacing the industry’s **10.4%** decline, and trades at a **7.3x forward P/S ratio**, above the industry average of **4.82x**. Competitors like **GE Healthcare** and **iRhythm** also advance AI-ECG tools, with iRhythm reporting **85% accuracy** in pilot programs for arrhythmia detection.

## Key points

- Tempus AI wins FDA clearance for two AI-ECG tools: Tempus ECG-MR and Tempus ECG-PH
- Market size for AI-ECG analysis grows from $2.01B in 2025 to $2.40B in 2026 at 19.3% CAGR
- Tempus stock down 17.7% year-over-year, trading at 7.3x forward P/S ratio

## Why it matters

FDA-cleared AI-ECG tools could improve early detection of heart conditions, reducing missed diagnoses and healthcare costs. Tempus’s move accelerates competition in a fast-growing market, but its valuation gap may limit investor confidence.

## Sources

1. [Here's How Tempus AI is Capitalizing on AI-ECG Market Growth](https://finance.yahoo.com/healthcare/articles/heres-tempus-ai-capitalizing-ai-140300775.html) (finance.yahoo.com, 2026-10-05)

## Cite

Digest AI, "Tempus AI wins FDA clearance for two AI-ECG tools", 5 October 2026, https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools

---

Written by Digest AI's editorial model from the linked sources; the sources are the record. Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse
JSON: https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools.json